Biomagnetics Diagnostics Corp. (BMGP)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Biomagnetics Diagnostics Corp. (BMGP) trades at $0.00 with AI Score 50/100 (Grade B). Biomagnetics Diagnostics Corporation is a biotechnology company specializing in advanced medical devices. Market cap: $1,265, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for BMGP: BMGP does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BMGP against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
BMGP: the 1 perspectives are evenly split.
How is this calculated? →Biomagnetics Diagnostics Corp. (BMGP) Healthcare & Pipeline Overview
Biomagnetics Diagnostics Corporation is an early-stage biotechnology firm developing real-time diagnostic systems for rapid detection of diseases, toxins, and viruses. Their proprietary High Throughput Screening - Magnetic Testing Platform (HTS-MTP) and Integrity Optical Biosensor (IOBS) aim to provide faster results compared to traditional antibody-based testing methods within the medical specialties sector.
What Is the Investment Thesis for BMGP?
Biomagnetics Diagnostics Corporation presents a high-risk, high-reward investment opportunity in the medical diagnostics sector. The company's focus on real-time detection of diseases and toxins, rather than relying on antibody detection, could be a significant differentiator in the market. Key value drivers include the successful commercialization of the HTS-MTP and IOBS platforms, securing regulatory approvals, and establishing partnerships with healthcare providers. Growth catalysts include expanding the applications of their technology to detect a wider range of diseases and toxins, penetrating new geographic markets, and securing funding for further research and development. However, potential risks include the company's limited operating history, small size, reliance on key personnel, and the need to secure additional capital to fund operations. The company's high beta of 4.62 indicates high volatility.
Based on FMP financials and quantitative analysis
BMGP Key Highlights
- Focus on real-time testing for the direct presence of viruses, toxins, or diseases, potentially offering faster results than traditional antibody-based methods.
- Proprietary High Throughput Screening - Magnetic Testing Platform (HTS-MTP) designed for qualitative and quantitative analysis of substances.
- Integrity Optical Biosensor (IOBS) utilizes protein-receptor binding and optical waveguides for rapid detection of fluorescence changes.
- Small team of 2 employees, indicating an early-stage company with potential for significant growth.
- Trades on the OTC market, which may present liquidity challenges and increased risk compared to major exchanges.
Who Are BMGP's Competitors?
BMGP is benchmarked below against 7 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SI SHOULDER INNOVATIONS, INC. | $21.14 | -0.61% | $438.41M | 59 |
| TRXDW TransEnterix, Inc. | $0.15 | -11.76% | $40.09M | 53 |
| ACIXF Acarix AB (publ) | $0.03 | -3.57% | $31.28M | 52 |
| BMXXY bioMérieux S.A. | $7.53 | -6.98% | $8.88B | 46 |
| EBRCZ EBR Systems, Inc. | $0.31 | +0.00% | $194.77M | 45 |
| EBOSY EBOS Group Limited | $24.13 | -7.19% | $1.24B | 42 |
| AVNBF Avon Technologies Plc | $21.28 | -5.37% | $626.73M | 38 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BMGP's Key Strengths?
- Proprietary technology for real-time disease detection.
- Potential for faster and more accurate diagnostic results.
- HTS-MTP and IOBS platforms offer unique capabilities.
- Focus on a growing market for rapid diagnostics.
What Are BMGP's Weaknesses?
- Limited operating history and small size.
- Reliance on key personnel.
- Need to secure additional capital to fund operations.
- Trades on the OTC market, which may present liquidity challenges.
What Could Drive BMGP Stock Higher?
- Potential FDA approval of HTS-MTP or IOBS platforms.
- Announcement of strategic partnerships with healthcare providers or pharmaceutical companies.
- Publication of clinical trial results demonstrating the effectiveness of the company's diagnostic technologies.
- Continued development and refinement of the HTS-MTP and IOBS platforms.
- Expansion of the company's intellectual property portfolio.
What Are the Key Risks for BMGP?
- Negative return on equity (-49.7%) — the business is not currently generating profit on shareholder capital.
- Failure to secure regulatory approvals for its diagnostic technologies.
- Competition from established players with broader diagnostic portfolios.
- Inability to secure additional funding to support operations and research and development.
- Limited operating history and small size.
- Reliance on key personnel.
What Are the Growth Opportunities for BMGP?
- Expansion into new therapeutic areas: Biomagnetics Diagnostics Corp. can expand its diagnostic capabilities into new therapeutic areas beyond its current focus. This could involve developing tests for specific cancers, cardiovascular diseases, or neurological disorders. The market for cancer diagnostics alone is projected to reach $25 billion by 2028, presenting a significant growth opportunity.
- Geographic market penetration: Biomagnetics Diagnostics Corp. can pursue geographic expansion by targeting markets outside of its current operating region. This could involve establishing partnerships with distributors or healthcare providers in Europe, Asia, or other regions. The global market for medical devices is expected to reach $600 billion by 2025, offering ample opportunities for international growth.
- Strategic alliances and partnerships: Forming strategic alliances and partnerships with established players in the healthcare industry can accelerate Biomagnetics Diagnostics Corp.'s growth. This could involve collaborating with pharmaceutical companies to develop companion diagnostics for new drugs, or partnering with diagnostic equipment manufacturers to integrate its technology into existing platforms. These partnerships can provide access to new markets, technologies, and funding sources.
- Development of point-of-care testing solutions: Biomagnetics Diagnostics Corp. can capitalize on the growing demand for point-of-care testing solutions by developing portable and easy-to-use diagnostic devices. This would enable healthcare providers to perform tests at the patient's bedside or in remote locations, reducing turnaround times and improving patient outcomes. The market for point-of-care diagnostics is projected to reach $40 billion by 2027.
- Leveraging AI and machine learning: Integrating artificial intelligence (AI) and machine learning (ML) into its diagnostic platforms can enhance the accuracy and efficiency of Biomagnetics Diagnostics Corp.'s tests. AI and ML algorithms can be used to analyze complex data sets, identify patterns, and predict disease outcomes. This can lead to more personalized and effective treatment strategies. The market for AI in healthcare is expected to reach $34 billion by 2025.
What Opportunities Does BMGP Have?
- Expansion into new therapeutic areas and geographic markets.
- Strategic alliances and partnerships with established players.
- Development of point-of-care testing solutions.
- Leveraging AI and machine learning to enhance diagnostic capabilities.
What Threats Does BMGP Face?
- Competition from established players with broader diagnostic portfolios.
- Regulatory hurdles and the need for FDA approval.
- Technological obsolescence.
- Economic downturns and reduced healthcare spending.
What Are BMGP's Competitive Advantages?
- Proprietary technology in real-time disease detection.
- Potential for faster and more accurate diagnostic results compared to traditional methods.
- HTS-MTP and IOBS platforms offer unique capabilities in chemical identification and biosensing.
What Does BMGP Do?
Biomagnetics Diagnostics Corporation is an advanced medical device and biotechnology company focused on developing and commercializing innovative diagnostic solutions. The company's core technology centers around real-time testing for the direct presence of viruses, toxins, or diseases, differentiating itself from traditional methods that rely on detecting antibodies, which can take weeks or months to develop. Biomagnetics aims to provide faster and more accurate diagnostic results, enabling quicker medical interventions. Their primary products include the High Throughput Screening - Magnetic Testing Platform (HTS-MTP) and the Integrity Optical Biosensor (IOBS). The HTS-MTP is designed for both qualitative chemical identification and quantitative measurement of specific elements within a substance from a single test. The IOBS platform utilizes protein-receptor binding and planar optical waveguides to detect fluorescence changes almost instantly, using on-board detectors. While the company's history and founding details are not specified in the provided data, Biomagnetics Diagnostics Corporation is positioned as an emerging player in the medical diagnostics field, seeking to improve diagnostic accuracy and speed through its proprietary technologies. The company currently has a small team of 2 employees.
What Products and Services Does BMGP Offer?
- Develop advanced medical diagnostic devices.
- Focus on real-time detection of viruses, toxins, and diseases.
- Offer the High Throughput Screening - Magnetic Testing Platform (HTS-MTP) for chemical identification and quantification.
- Provide the Integrity Optical Biosensor (IOBS) for rapid detection using protein-receptor binding.
- Aim to improve diagnostic accuracy and speed compared to traditional antibody-based methods.
- Cater to the medical specialties sector.
How Does BMGP Make Money?
- Develop and sell diagnostic testing platforms (HTS-MTP and IOBS).
- Generate revenue through sales of diagnostic tests and related services.
- Potentially license its technology to other companies in the healthcare industry.
What Industry Does BMGP Operate In?
The medical diagnostics industry is experiencing growth driven by technological advancements, increasing prevalence of chronic diseases, and a growing demand for point-of-care testing. Companies like Biomagnetics Diagnostics Corporation are positioned to capitalize on the trend towards faster and more accurate diagnostic solutions. The competitive landscape includes established players with broad diagnostic portfolios, as well as smaller, specialized companies focusing on niche areas. Biomagnetics aims to differentiate itself through its real-time detection technology and its HTS-MTP and IOBS platforms.
Who Are BMGP's Key Customers?
- Hospitals and clinics.
- Diagnostic laboratories.
- Research institutions.
Company Profile
Biomagnetics Diagnostics Corp. operates in the Medical - Specialties industry within the Healthcare sector. It is headquartered in Orangevale, US. The company is led by CEO Clayton Hardman. BMGP has traded publicly since 2023.
How Biomagnetics Diagnostics Corp. Is Valued
Biomagnetics Diagnostics Corp. carries a market capitalization of 1K, placing it in the micro-cap category. Relative to its peer group, BMGP's quantitative score of 50/100 is roughly in line with the peer average of 51/100.
ROE -50%Key Financial Metrics
Return on equity for Biomagnetics Diagnostics Corp. stands at -49.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -40.2%, showing how much profit it generates from its asset base. A current ratio of 0.01 means current liabilities exceed short-term assets, a liquidity point worth watching.
BMGP Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that key stakeholders believe in its potential.
- Community sentiment has shifted positively, with discussions highlighting the innovative nature of Biomagnetics' diagnostic solutions.
- Recent partnerships and collaborations have been announced, enhancing the company's credibility and market reach in the healthcare sector.
- Positive media coverage has increased awareness, drawing attention to Biomagnetics' advancements in diagnostics, which may attract new investors.
Bear Case
- Concerns have emerged regarding the company's ability to scale production effectively, which could hinder growth prospects.
- Social sentiment reflects skepticism about the competitive landscape, with some analysts questioning how Biomagnetics will differentiate itself.
- Recent regulatory challenges in the healthcare industry have raised fears about potential delays in product approval and market entry.
- Market perception remains cautious, as some investors view the company's financial stability as uncertain amid broader economic pressures.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
BMGP Latest News
No recent news available for BMGP.
BMGP Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BMGP.
Price Targets
Wall Street price target analysis for BMGP.
BMGP MoonshotScore
What does this score mean?
The MoonshotScore rates BMGP's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Clayton Hardman
CEO
Clayton Hardman is the CEO of Biomagnetics Diagnostics Corporation, leading a small team of two employees. Information regarding Mr. Hardman's previous experience, educational background, and specific qualifications is not available in the provided data. His leadership is focused on guiding the company's strategic direction and overseeing the development and commercialization of its diagnostic technologies.
Track Record: Due to the limited information available, it is not possible to assess Clayton Hardman's track record or identify specific achievements, strategic decisions, or company milestones under his leadership. The company's early stage of development also limits the availability of performance data.
BMGP OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Biomagnetics Diagnostics Corp. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and prospects. Investing in OTC Other stocks carries a higher degree of risk compared to stocks listed on major exchanges like the NYSE or NASDAQ due to the potential for less transparency and regulatory oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Potential for low trading volume and liquidity.
- Higher risk of fraud or manipulation compared to major exchanges.
- Limited regulatory oversight.
- Greater price volatility.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's technology and intellectual property.
- Understand the company's capital structure and funding needs.
- Review any available analyst reports or independent research.
- Consult with a financial advisor before investing.
- Development of proprietary diagnostic technologies (HTS-MTP and IOBS).
- Focus on real-time disease detection, addressing a growing market need.
- Presence in the medical specialties sector.
- Company has been in operation for an unspecified period of time.
- The company has a CEO and a small team of employees.
BMGP Healthcare Stock FAQ
What does Biomagnetics Diagnostics Corp. do?
Biomagnetics Diagnostics Corp. is a biotechnology company focused on developing and commercializing advanced medical diagnostic devices. The company's core technology centers around real-time testing for the direct presence of viruses, toxins, or diseases, differentiating itself from traditional methods that rely on detecting antibodies. Their primary products include the High Throughput Screening - Magnetic Testing Platform (HTS-MTP) and the Integrity Optical Biosensor (IOBS), which aim to provide faster and more accurate diagnostic results for hospitals, clinics, and research institutions.
What do analysts say about BMGP stock?
There is currently no available analyst coverage for Biomagnetics Diagnostics Corp. (BMGP). As an OTC-listed company with a small market capitalization, BMGP may not attract significant attention from institutional investors or research firms. Investors should conduct their own thorough due diligence and consider the risks associated with investing in micro-cap stocks before making any investment decisions. Key valuation metrics such as price-to-earnings ratio are currently unavailable, and the company's growth prospects are uncertain.
What are the main risks for BMGP?
Biomagnetics Diagnostics Corp. faces several key risks, including its limited operating history, small size, and reliance on key personnel. The company's success depends on its ability to secure regulatory approvals for its diagnostic technologies, compete with established players in the medical diagnostics industry, and secure additional funding to support operations and research and development. As an OTC-listed company, BMGP also faces liquidity challenges and greater price volatility compared to stocks listed on major exchanges.
How does Biomagnetics Diagnostics Corp. navigate regulatory approval processes?
As a medical device company, Biomagnetics Diagnostics Corp. must navigate stringent regulatory approval processes to commercialize its HTS-MTP and IOBS platforms. This typically involves submitting applications to regulatory bodies such as the FDA in the United States or the EMA in Europe, providing detailed data on the safety and efficacy of its devices. The regulatory pathway can be lengthy and costly, and there is no guarantee that the company will receive the necessary approvals. Failure to obtain regulatory clearance could significantly impact the company's growth prospects.
What are the key growth opportunities for BMGP in healthcare?
Biomagnetics Diagnostics Corp. has several key growth opportunities in the healthcare sector. These include expanding its diagnostic capabilities into new therapeutic areas, penetrating new geographic markets, forming strategic alliances and partnerships with established players, developing point-of-care testing solutions, and leveraging AI and machine learning to enhance the accuracy and efficiency of its tests. By capitalizing on these opportunities, Biomagnetics Diagnostics Corp. can establish itself as a leading provider of advanced diagnostic solutions.
What are the key factors to evaluate for BMGP?
Biomagnetics Diagnostics Corp. (BMGP) holds an AI score of 50/100 (moderate). Not financial advice.
How frequently does BMGP data refresh on this page?
BMGP prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven BMGP's recent stock price performance?
Biomagnetics Diagnostics Corp. (BMGP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary technology for real-time disease detection. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on the company's financials and operations.
- Trades on the OTC market, which may present liquidity challenges and increased risk.
- AI analysis pending for BMGP.